Quinidine: A valuable medication joins the list of 'endangered species'

Europace

Volumn 9, Issue 12, 2007, Pages 1105-1106

  Viskin, Sami ^a   Antzelevitch, Charles ^b   Márquez, Manlio F ^c   Belhassen, Bernard ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; IBUTILIDE; QUINIDINE SULFATE; SOTALOL; ANTIARRHYTHMIC AGENT; QUINIDINE;

BRUGADA SYNDROME; DEFIBRILLATOR; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MANUFACTURE; EDITORIAL; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; PRIORITY JOURNAL; SHORT QT SYNDROME; DRUG CONTROL; HEART ARRHYTHMIA; PATHOPHYSIOLOGY;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; BRUGADA SYNDROME; DEFIBRILLATORS, IMPLANTABLE; DRUG AND NARCOTIC CONTROL; ELECTROCARDIOGRAPHY; HUMANS; QUINIDINE; VENTRICULAR FIBRILLATION;

EID: 39849084701     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eum181     Document Type: Editorial

References (18)

1. Dear pharmacist letter: Discontinuation of quinidine bisulphate. http://www.shpa.org.au/pdf/manuf_alerts/kinidin_may06.pdf (2006)
2. Kaufman ES. Quinidine in short QT syndrome: an old drug for a new disease. J Cardiovasc Electrophysiol 2007;18:665-6.
3. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731-7.
4. Belhassen B, Shapira I, Shoshani D, Paredes A, Miller H, Laniado S. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987;75:809-16.
5. Milberg P, Tegelkamp R, Osada N, Schimpf R, Wolpert C, Breithardt G et al. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol 2007;18:658-64.
6. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 2005;16:54-8.
7. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calo L et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004;43:1494-9.
8. Chen Q, Kirsch G, Zhang D, Brugada R, Brugada J, Brugada P et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293.
9. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115:442-9.
10. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:513-6.
11. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004;43:1853-60.
12. Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J 1990;120:661-71.
13. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:1301-12.
14. Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol 2002;25:1634-40.
15. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gerard F et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006;114:2317-24.
16. Marquez MF, Salica G, Hermosillo AG, Pastelin G, Gomez-Flores J, Nava S et al. Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol 2007;18:234-40.
17. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita Tet al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007;4:695-700.
18. Shvilkin A. Treatment of ventricular fibrillation storm in Brugada syndrome: weathering the storm but staying in hot water? Heart Rhythm 2007;4:701-2.